Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Hypoparathyroidism Market?
The market size of hypoparathyroidism has seen significant growth over the recent years. The market, which is valued at $0.95 billion in 2024, is projected to increase to $1.03 billion in 2025, experiencing a compound annual growth rate (CAGR) of 8.6%. The surge during the historic period can be linked to the escalating number of thyroid surgeries, growing awareness concerning hypoparathyroidism, increase in postoperative complications, rising demand for vitamin D and calcium supplements, and an enhanced attention to endocrine disorder management.
Expectations are high for robust expansion in the hypoparathyroidism market, which is predicted to surge to $1.42 billion by 2029, progressing at a compound annual growth rate (CAGR) of 8.3%. This projected growth over the forecast period is largely due to the increased acceptance of recombinant parathyroid hormone treatments, amplified investment in hypoparathyroidism studies, development of healthcare infrastructure, growth of elderly population susceptible to endocrine disorders, and rising early detection initiatives and awareness. Noteworthy trends expected in the forecast period encompass advancements in parathyroid hormone treatments, sophisticated diagnostic methodologies for hypoparathyroidism, formulation of long-lasting calcium supplements, introduction of less invasive procedures in thyroid surgery, and progress in patient surveillance technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24565&type=smp
Which Factor Is Shaping The Future Of The Hypoparathyroidism Market?
The escalating instances of thyroid cancer are anticipated to contribute significantly to the expansion of the hypoparathyroidism market in upcoming years. Thyroid cancer is distinguished by unusual cell growth in the thyroid gland, often culminating in a neck lump. The surge in thyroid cancer instances can be attributed to the improved diagnostic imaging technologies, which have facilitated prompt and regular detection of small, symptom-less thyroid nodules. The unfettered progression of thyroid cancer propels hypoparathyroidism, as it escalates the necessity for thyroid surgeries. These surgeries hold the potential of unintentionally damaging the parathyroid glands, causing imbalance in calcium and chronic hormone deficiency. This necessitates long-term disease management solutions. To illustrate, the American Cancer Society, a non-profit organization based in the US, stated in May 2024 that there was an escalation in new thyroid cancer cases from 43,720 in 2023 to 44,020 in 2025. For these reasons, the surge in thyroid cancer cases is fuelling the growth of the hypoparathyroidism market.
What Is The Segment-Wise Breakdown Of The Hypoparathyroidism Market?
The hypoparathyroidism market covered in this report is segmented –
1) By Treatment: Hormone Replacement Therapy, Adjunctive Therapies
2) By Type: Hormone Replacement Therapy, Calcium And Vitamin D Supplements, Emerging Therapies
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues, Calcimimetics, Calcium And Vitamin D Supplements
2) By Adjunctive Therapies: Magnesium Supplements, Phosphate Binders, Other Supportive Therapies
Which Trends Are Redefining The Future Landscape Of The Hypoparathyroidism Industry?
Large corporations in the hypoparathyroidism market are honing their focus on creating products with advanced technology, such as those using transition technology, to increase the effectiveness of treatment and better patient outcomes. Products based on TransCon technology are created using TransCon (Transient Conjugation) technology, an exclusive platform that enhances drug administration. For instance, in January 2024, Ascendis Pharma A/S, originating from Denmark and involved in biopharmaceuticals, launched its second product based on TransCon technology named YORVIPATH (palopegteriparatide), in Germany and Austria with the specific purpose of treating adults dealing with chronic hypoparathyroidism. YORVIPATH, a prodrug of parathyroid hormone (PTH 1-34) taken once daily, is designed to manage the physiologic PTH levels for a full day, effectively dealing with the hormonal insufficiencies linked to chronic hypoparathyroidism.
Which Companies Hold The Largest Market Share In The Hypoparathyroidism Sector?
Major companies operating in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/hypoparathyroidism-global-market-report
How Does Regional Performance Compare Across The Hypoparathyroidism Industry?
North America was the largest region in the hypoparathyroidism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypoparathyroidism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24565&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model